



Euroz Hartleys 2026 Healthcare Forum

Gary Phillips, CEO

5 February 2026

FORWARD LOOKING STATEMENT

This document contains forward-looking statements, including statements concerning Syntara's future financial position, plans, and the potential of its products and product candidates, which are based on information and assumptions available to Syntara as of the date of this document. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements.

These forward-looking statements are not guarantees or predictions of future results, levels of performance, and involve known and unknown

risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results to differ materially from those expressed in the statements contained in this document. For example, despite our efforts there is no certainty that we will be successful in developing or partnering any of the products in our pipeline on commercially acceptable terms, in a timely fashion or at all. Except as required by law we undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise.

INVESTMENT HIGHLIGHTS



Australian-founded
**clinical stage
drug developer.**



Backed **by
specialist healthcare
investors** –
43% institutional.



**Multiple shots on
goal** from additional
Phase 2, Phase 1 and
preclinical assets.



Funded into 2027 with
**near term data to drive
value** over the next
12-18 months.
(Proforma Dec 25; \$12.3m)



Focus on first-in-class
and best-in-class drugs
backed by **in house long-life
patent portfolio.**



Experienced team
with **proven track
record** in licensing
deals – \$100m raised.



Three Phase 2 studies in
blood cancer indications
with addressable market
value >\$4.5 bn.



\$11.5m in non-dilutive
grant funding
awarded in last 3 years.

POSITIVE 52 WEEK TOP LINE DATA FROM PHASE 2 BLOOD CANCER TRIAL
Safety and tolerability of amsulostat, together with the increasing size and durability of clinical
benefit seen beyond 24 weeks, compares very favourably with other drugs in development

SHAREHOLDERS & CASH

Financial Information (ASX: SNT)

Share price – 02 February 2026	\$0.032
Market cap	A\$52.2m
Cash balance – 31 December 2025	A\$12.3m
Enterprise value	A\$39.9m

Institutional Ownership 30 Sept 25

D&A Income Limited	18%
Platinum Investment Management Limited	10%

Total Institutional Ownership > **43.4%**

Research Coverage

Canaccord Genuity	Euroz Hartleys
Bell Potter	Evolution Capital

Share Price & Volume – YTD



* 21 May 2025 recorded volume was 303,525,200 due to internal crossing of stock by substantial holder (maintains same beneficial owner)
** 19 June 2025 recorded volume was 127,701,110 due to block trade of shares between institutions
*** 11 August 2025 recorded volume was 119,820,710 following announcement of FDA guidance for amsulostat

SYNTARA BOARD

Significant international pharmaceutical experience



Dr Kathleen Metters
Chair

- Former Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of the company's global research projects.
- In a subsequent role at Merck & Co she led work on External Discovery and Preclinical Sciences 1a).
- Former CEO of biopharmaceutical company Lycera Corp.



Dr Simon Green
Non-Executive Director

- Experienced senior global pharma executive with 30 years' of experience in the biotechnology industry.
- Actively involved in CSL's global expansion over a 17-year period where he held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL's manufacturing plants in Germany and Australia.
- Prior to joining CSL he worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation.



Gary Phillips
Chief Executive Officer

- 30+ years' of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.
- Joined Syntara in 2003 and was appointed Chief Executive Officer in March 2013 at which time he was Chief Operating Officer.
- Previously held country and regional management roles at Novartis – Hungary, Asia Pacific and Australia.



Hashan De Silva
Non-Executive Director

- Experienced life sciences investment professional with extensive knowledge of the biotech, pharmaceutical and medical technology sectors.
- Worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research.
- Prior to moving into life science investment Hashan worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.

2025 ACHIEVEMENTS

- **Lead asset amsulostat continues to build momentum**

- Amsulostat Phase 2a myelofibrosis clinical trial completed and presented at American Society of Hematology Annual Meeting in Orlando
- Two myelodysplastic syndrome (MDS) Phase 2 studies initiated with launch of amsulostat German AZALOX and Australian MESSAGE trials
- Regulatory guidance on clinical development path in myelofibrosis provided by FDA and positive European Medicines Agency opinion received for Orphan Drug Designation of amsulostat in myelofibrosis
- Pancreatic cancer Phase 1/2 clinical trial of amsulostat in collaboration with the Garvan, funded by MRFF

- **Pipeline assets progress**

- SNT-4728 Phase 2 iRBD trial fully recruited with data expected in Q2 2026, triggering payment of \$1.8 million expected in Q1 2026
- Progression of topical anti-fibrotic SNT-9465 into hypertrophic scar study following successful completion of Phase 1a study



MYELOFIBROSIS

KEY FACTS

- Orphan disease affects ~15 in 1m people worldwide (USA ~ 20,000 patients)
- Age of onset typically from age 50; 5 years median survival
- 11% transformation to leukemia
- Reduced red blood cells can cause extreme tiredness (fatigue) or shortness of breath
- Reduced white blood cells can lead to an increased number of infections
- Reduced platelets can promote bleeding and/or bruising
- Enlarged spleen due to insufficient healthy blood cell production from the bone marrow causing abdominal pain
- Other common symptoms include fever, night sweats, and bone pain

A rare type of bone marrow cancer that disrupts the body's normal production of blood cells

Myelofibrosis characterised by a build up of scar tissue (fibrosis) in bone marrow and abnormal proliferation of blood precursor cells reducing the production of blood cells




MYELOFIBROSIS

Limited treatment options currently

Current standard of care (SoC): JAK inhibitors

- Class of drugs used in the management of splenomegaly (enlarged spleen) and other constitutional symptoms



- Symptom improvement assessed using patient reported questionnaire that provides **Total Symptom Score (TSS)**
- CT or MRI scan used to measure **spleen volume reduction (SVR)**

JAK inhibitors have significant limitations

- Offer limited survival benefits and are associated with significant dose-limiting tolerability issues including cytopenias and increased risk of infection
- 75% discontinuation at 5 years
- Median overall survival only 14 – 16 months after discontinuation

Amsulostat

In contrast to SoC, amsulostat intervenes at the source, clearing fibrosis from the bone marrow and reducing growth factor activity; thus enabling increased production of healthy blood cells

Clinical positioning:

- ✓ Distinct mode of action
- ✓ Improved tolerability
- ✓ Profile suitable for combination with SoC
- In addition to symptomatic relief, potential for disease modification.

Commercial Opportunity

- Current SoC; revenue ~US\$1.9b per annum
- Recent biotech exits after Phase 3 in excess of US\$1.7b


TOTAL SYMPTOM SCORE

73% (8/11) of patients achieved TSS50 at Week 24 or beyond

Symptom relief continues for patients:

- 73% (8/11) patients* achieved TSS50 at Week 24 or beyond
- Mean TSS reduction from baseline to Week 38 (n=8) was 56%
- Mean TSS reduction from baseline to Week 52 (n=7) was 68%

* Results for TSS50 at Week 24 or beyond are for the 11 patients reaching Week 24



SPLEEN VOLUME REDUCTION


44% (4/9) of patients achieved SVR25 at Week 24 or beyond

Improved spleen volume reduction:

- At Week 24, 7/9 (78%) evaluable patients* experienced stable or reduced spleen volume with no increases in RUX dose.
- 4/9 (44%) evaluable patients achieved SVR25 at Week 24 or beyond
- Of the 2 patients that reached 52 weeks (in addition to the 5 reported at EHA**) one patient retained SVR25 at Week 52

* Evaluable patients are those who had spleen volume $\geq 450\text{ cm}^3$ at baseline and with $\geq 80\%$ RUX use

** Watson et al. HemaSphere, 2025;9:(S1) PS1832



POSITIVE TOP LINE PHASE 2A DATA HIGHLIGHTS

AMSULOSTAT'S POTENTIAL IN MYELOFIBROSIS

Improvements of 50% or more in total symptom score (TSS50)

were observed quickly (as early as 12 weeks) and were sustained, with 73% (8/11) of patients achieving TSS50 at Week 24 or beyond

Meaningful spleen volume reductions (SVR) were observed

at 24 weeks and maintained thereafter, with 44% (4/9) of patients achieving SVR25 at Week 24 or beyond

Of the 7 patients that completed 52 weeks of treatment

- 6 chose to continue on amsulostat through named patient supply
- 3 of these patients had a minor anaemia response*
- 2 achieved a complete (100%) resolution of symptoms from baseline

Next stage of amsulostat clinical development and partnership engagement triggered

- Experienced global MF experts appointed in key advisory roles
- FDA approved development plan and partner engagement in H1 2026




* 2024 proposed IWG-ELN criteria

STRONG INTEREST IN MF ASSETS FROM STRATEGICS

Target / Acquiror	 	 	 	 
DATE OF ANNOUNCEMENT	DEC-2024	FEB-2024	JUNE-2023	JULY-2022
Drug Name	Elritercept	Pelabresib	Pacritinib	Momelotinib
Lead Indication / Phase (at transaction)	MDS and MF (ongoing Phase 2 trials)	Myelofibrosis (successful Phase 3 studies)	Myelofibrosis (Marketed)	Myelofibrosis (NDA Filed)
Deal Type	License	Acquisition	Acquisition	Acquisition
Upfront / Milestones (US\$)	US\$200M / US\$1.1B	US\$2.9B	US\$1.7B	US\$1.9B
Earnout Payments / Royalty Rate (%)	Not disclosed	Subject to regulatory approvals	None	None

Attractive commercial outcomes for drugs with Phase 2 and 3 data expected to drive interest in amsulostat Phase 2 data

THE YEAR AHEAD - POISED TO DELIVER NEAR TERM VALUE

TARGET	DRUG	INDICATION	PARTNERS	PHASE 1		PHASE 2	NEWS FLOW	
				HEALTHY PARTICIPANTS	PATIENTS		H1 2026	H2 2026
Pan-LOX	Amsulostat (SNT-5505)	Myelofibrosis					FDA approved development plan and partner engagement	
		High Risk MDS AZALOX trial					Interim safety and efficacy data	Phase 2 initiation
		Low / Int Risk MDS MESSAGE trial						Interim safety and efficacy data
		Pancreatic cancer						Trial initiation
Topical Pan-LOX	SNT-9465	Hypertrophic scarring					Recruit hypertrophic scar Phase 1b trial	Top Line safety and efficacy data
	SNT-6302	Keloid scarring					Interim safety and efficacy data	
Dual SSAO & MAO-B	SNT-4728	IRBD / Parkinson's Disease	In partnership with 				Phase 2 Top Line data	

2026 – Outlook Webinar: Held on 3rd February 2026

Participants



Hashan De Silva
Non Executive Director



Gary Phillips
CEO

Link to webinar:
<https://youtu.be/XiWqRdZKWhE>



Syntara Limited ABN 75 082 811 630

www.syntaraTX.com.au



Gary Phillips

Chief Executive Officer

gary.phillips@syntaraTX.com.au